Jump to content

PubMed RSS Feed - - [Are there any clinical evaluations confirming higher incidence of skin cancers as a result of pimecrolimus therapy?]


rss

Recommended Posts

Related Articles

[Are there any clinical evaluations confirming higher incidence of skin cancers as a result of pimecrolimus therapy?]

Pol Merkur Lekarski. 2008 Sep;25(147):284-7

Authors: Barańjska-Rybak W, Nowicki R, Sokołowska-Wojdyło M, Roszkiewicz J

Pimecrolimus (SDZ ASM 981), nonsteroid anty-inflammatory ackomycin-derived drug has more and more indications in dermatology. It has been recommended in therapy of atopic and contact dermatitis at the beginning. Nowadays pimecrolimus is used in the treatment of seborrhoic dermatitis, post-steroidal rosacea, bullous diseases etc. News reporting higher incidence of skin cancers after pimecrolimus application has not been proved clinically. The common use of mentioned medication forced us to detailed analysis of references concerning that problem.

PMID: 19112851 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...